UCB S.A. – Product Pipeline Review

Global Markets Direct’s, ‘UCB S.A. – Product Pipeline Review – 2016’, provides an overview of the UCB S.A.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by UCB S.A., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of UCB S.A.

The report provides overview of UCB S.A. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses UCB S.A.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features UCB S.A.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate UCB S.A.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for UCB S.A.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding UCB S.A.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

UCB S.A. Snapshot 6

UCB S.A. Overview 6

Key Information 6

Key Facts 6

UCB S.A. - Research and Development Overview 7

Key Therapeutic Areas 7

UCB S.A. - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Pipeline Products - Partnered Products 12

Partnered Products/Combination Treatment Modalities 13

Pipeline Products - Out-Licensed Products 14

Out-Licensed Products/Combination Treatment Modalities 15

UCB S.A. - Pipeline Products Glance 16

UCB S.A. - Late Stage Pipeline Products 16

Pre-Registration Products/Combination Treatment Modalities 16

Phase III Products/Combination Treatment Modalities 17

UCB S.A. - Clinical Stage Pipeline Products 18

Phase II Products/Combination Treatment Modalities 18

Phase I Products/Combination Treatment Modalities 19

UCB S.A. - Early Stage Pipeline Products 20

Preclinical Products/Combination Treatment Modalities 20

Discovery Products/Combination Treatment Modalities 21

UCB S.A. - Drug Profiles 22

brivaracetam 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

certolizumab pegol 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

lacosamide 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

levetiracetam 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

rotigotine ER 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

bimekizumab 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

seletalisib 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

UCB-0942 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

UCB-7665 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

dapirolizumab pegol 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

UCB-4144 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

UCB-6673 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

Antibodies for Cancer, Immunology and Inflammation 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

Monoclonal Antibody to Inhibit Fatty Acid-Binding Protein 4 for Diabetes and Metabolic Disorders 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

Recombinant Protein to Inhibit TNF-Alpha for Alzheimer's Disease 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

Antibody to Inhibit Transglutaminase 2 for Fibrosis 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

Small Molecules to Inhibit Kinase for Neurodegenerative Diseases 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

UCB S.A. - Pipeline Analysis 59

UCB S.A. - Pipeline Products by Target 59

UCB S.A. - Pipeline Products by Route of Administration 61

UCB S.A. - Pipeline Products by Molecule Type 62

UCB S.A. - Pipeline Products by Mechanism of Action 63

UCB S.A. - Recent Pipeline Updates 65

UCB S.A. - Dormant Projects 81

UCB S.A. - Discontinued Pipeline Products 82

Discontinued Pipeline Product Profiles 82

CDP-323 82

CDP-435 82

CDP-484 82

lacosamide 82

seletracetam 83

UCB-2892 83

UCB S.A. - Company Statement 84

UCB S.A. - Locations And Subsidiaries 86

Head Office 86

Other Locations & Subsidiaries 86

Appendix 90

Methodology 90

Coverage 90

Secondary Research 90

Primary Research 90

Expert Panel Validation 90

Contact Us 90

Disclaimer 91

List of Tables

List of Tables

UCB S.A., Key Information 6

UCB S.A., Key Facts 6

UCB S.A. – Pipeline by Indication, 2016 8

UCB S.A. – Pipeline by Stage of Development, 2016 10

UCB S.A. – Monotherapy Products in Pipeline, 2016 11

UCB S.A. – Partnered Products in Pipeline, 2016 12

UCB S.A. – Partnered Products/ Combination Treatment Modalities, 2016 13

UCB S.A. – Out-Licensed Products in Pipeline, 2016 14

UCB S.A. – Out-Licensed Products/ Combination Treatment Modalities, 2016 15

UCB S.A. – Pre-Registration, 2016 16

UCB S.A. – Phase III, 2016 17

UCB S.A. – Phase II, 2016 18

UCB S.A. – Phase I, 2016 19

UCB S.A. – Preclinical, 2016 20

UCB S.A. – Discovery, 2016 21

UCB S.A. – Pipeline by Target, 2016 59

UCB S.A. – Pipeline by Route of Administration, 2016 61

UCB S.A. – Pipeline by Molecule Type, 2016 62

UCB S.A. – Pipeline Products by Mechanism of Action, 2016 64

UCB S.A. – Recent Pipeline Updates, 2016 65

UCB S.A. – Dormant Developmental Projects,2016 81

UCB S.A. – Discontinued Pipeline Products, 2016 82

UCB S.A., Subsidiaries 86

List of Figures

List of Figures

UCB S.A. – Pipeline by Top 10 Indication, 2016 8

UCB S.A. – Pipeline by Stage of Development, 2016 10

UCB S.A. – Monotherapy Products in Pipeline, 2016 11

UCB S.A. – Partnered Products in Pipeline, 2016 12

UCB S.A. – Out-Licensed Products in Pipeline, 2016 14

UCB S.A. – Pipeline by Top 10 Target, 2016 59

UCB S.A. – Pipeline by Route of Administration, 2016 61

UCB S.A. – Pipeline by Molecule Type, 2016 62

UCB S.A. – Pipeline Products by Top 10 Mechanism of Action, 2016 63

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports